NCT01599637View on ClinicalTrials.gov

Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Chronic Idiopathic Urticaria
Interventions
DRUG

IGE025

Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.

DRUG

placebo

Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.

Trial Locations (4)

10117

Novartis Investigative Site, Berlin

48149

Novartis Investigative Site, Münster

55131

Novartis Investigative Site, Mainz

01307

Novartis Investigative Site, Dresden

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY